Back to search results
NCT07587008

Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers

Completed
PHASE1Ages 18–55InterventionalBasic science
AbbVie
~12 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:Emraclidine

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AEs)
Measured over Up to approximately 44 days
+3 more outcomes measured

Conditions

Healthy Volunteers

Explore related trials

Healthy Volunteers

NCT07587008

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Acpru /Id# 283349

    Grayslake, Illinoisno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Body mass index of 18.5 to 32.0 kg/m2, inclusive.
Total body weight \>= 50 kg.

Exclusion

History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement.
Vital sign measurements, at Screening and Check-in:
Systolic blood pressure \>= 140 mmHg or \< 100 mmHg
Diastolic blood pressure \>= 90 mmHg or \< 60 mmHg
Heart rate \> 100 bpm or \< 50 bpm
Orthostatic hypotension, defined as a decrease of \>= 20 mmHg in systolic blood pressure upon standing compared with the supine/sitting blood pressure measurement.
Female participants of childbearing potential

What this trial measures

  • Number of Participants with Adverse Events (AEs)Up to approximately 44 days

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

  • Maximum Observed Plasma Concentration (Cmax) of EmraclidineUp to approximately 14 days

    Cmax of Emraclidine.

  • Time to Cmax (Tmax) of EmraclidineUp to approximately 14 days

    Tmax of Emraclidine.

  • Area Under the Concentration-Time Curve from Time 0 to Time t (AUC) of EmraclidineUp to approximately 14 days

    AUC of Emraclidine.